CI
HALO icon

Cigna Investments’s Halozyme HALO Stock Holding History

Cigna Investments’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,734
Closed -$229K – 742
2018
Q3 		$229K Sell
14,734
-66,308
-82% -$1.16M 0.02% 654
2018
Q2 		$1.37M Buy
81,042
+65,738
+430% +$1.24M 0.1% 182
2018
Q1 		$299K Buy
+15,304
New +$296K 0.02% 650

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Cigna Investments's HALO Position: Q4 2018 in Review

Cigna Investments sold out of Halozyme (HALO) in Q4 2018, closing a stake of 14,734 shares — an estimated $229K sold.

Cigna Investments first reported a position in HALO in Q1 2018 and held it in 3 quarters. The position peaked at $1.37M in Q2 2018. 195 funds tracked by Wall St. Rank hold HALO as of Q4 2018.

  • Cigna Investments reported no remaining Halozyme position as of Q4 2018 after selling out during the quarter.
  • Cigna Investments sold 14,734 Halozyme shares in Q4 2018, an estimated $229K.
  • Cigna Investments first reported a position in Halozyme in Q1 2018 and held it in 3 quarters.
  • Cigna Investments's Halozyme position peaked at $1.37M in Q2 2018.
  • 195 funds tracked by Wall St. Rank held Halozyme as of Q4 2018.

Based on Cigna Investments's 13F filing for Q4 2018, filed 6 Feb 2019.